Profile data is unavailable for this security.
About the company
AbbVie Inc. is a diversified research-based biopharmaceutical company engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. It offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383 for the treatment of inflammatory bowel disease.
- Revenue in USD (TTM)55.53bn
- Net income in USD5.08bn
- Incorporated2012
- Employees50.00k
- LocationAbbVie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
- Phone+1 (847) 932-7900
- Fax+1 (302) 655-5049
- Websitehttps://www.abbvie.com/
Mergers & acquisitions
| Acquired company | ABBV:NYQ since announced | Transaction value |
|---|---|---|
| Aliada Therapeutics Inc | -8.58% | 1.40bn |
| Celsius Therapeutics Inc | 0.34% | 250.00m |
| Cerevel Therapeutics Holdings Inc | 18.79% | 8.70bn |
| ImmunoGen Inc | 23.99% | 10.22bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc | 32.53bn | 4.23bn | 155.83bn | 26.70k | 37.09 | 20.70 | 15.89 | 4.79 | 7.82 | 7.82 | 60.33 | 14.00 | 0.3587 | 2.08 | 4.83 | 1,218,502.00 | 4.66 | 10.36 | 5.87 | 13.06 | 60.48 | 75.41 | 13.00 | 26.51 | 0.9553 | 2.62 | 0.8892 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Merck & Co Inc | 63.17bn | 12.15bn | 252.61bn | 72.00k | 20.94 | 5.68 | 15.38 | 4.00 | 4.77 | 4.77 | 24.95 | 17.58 | 0.5634 | 2.39 | 5.80 | 877,416.70 | 10.85 | 7.70 | 14.19 | 10.29 | 76.59 | 72.26 | 19.25 | 15.03 | 1.15 | 24.33 | 0.4611 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| AbbVie Inc | 55.53bn | 5.08bn | 303.47bn | 50.00k | 59.91 | 50.31 | 22.46 | 5.46 | 2.87 | 2.87 | 31.32 | 3.41 | 0.3972 | 4.31 | 4.85 | 1,110,660.00 | 3.67 | 6.55 | 5.09 | 8.40 | 67.25 | 69.74 | 9.24 | 16.46 | 0.5419 | 7.88 | 0.9213 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
| Johnson & Johnson | 87.70bn | 14.77bn | 374.39bn | 131.90k | 25.56 | 5.34 | 16.98 | 4.27 | 6.08 | 6.05 | 36.12 | 29.14 | 0.5094 | 2.27 | 5.66 | 664,867.30 | 8.58 | 8.93 | 11.90 | 11.96 | 69.16 | 68.17 | 16.84 | 18.86 | 0.7853 | -- | 0.3376 | 71.25 | 6.46 | 0.8622 | -18.59 | -2.72 | 4.36 | 5.83 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 163.41m | 9.25% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 89.19m | 5.05% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 79.07m | 4.48% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2024 | 36.79m | 2.08% |
| Geode Capital Management LLCas of 30 Sep 2024 | 36.16m | 2.05% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 33.21m | 1.88% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 32.46m | 1.84% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2024 | 23.84m | 1.35% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 22.48m | 1.27% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 21.84m | 1.24% |
